Breakthrough Proposal from Singapore's Research Powerhouses

Singapore's medical research landscape is making headlines with a groundbreaking review paper proposing lymphovenous anastomosis (LVA), also known as lymphovenous bypass, as a minimally invasive surgical approach to treat Alzheimer's disease (AD). Published in the March 2026 issue of Plastic and Reconstructive Surgery, the study highlights how enhancing brain lymphatic drainage could clear neurotoxins like amyloid-beta plaques and tau proteins, addressing a key pathological mechanism in AD.

Led by an interdisciplinary team from Duke-NUS Medical School, Singapore General Hospital (SGH), and the National Neuroscience Institute (NNI), this work underscores Singapore's position as a hub for innovative neuroscience. Duke-NUS, a graduate-level medical school jointly established by Duke University and the National University of Singapore (NUS), brings cutting-edge academic rigor to clinical challenges. The collaboration exemplifies how higher education institutions in Singapore are driving translational research to combat neurodegenerative diseases.

Alzheimer's affects approximately 74,000 Singaporeans as of 2023, with prevalence at 8.8% among those aged 60 and above—a figure expected to rise with the nation's aging population. This proposal arrives at a critical time, offering hope for novel interventions beyond current pharmaceuticals.

The Glymphatic System: Brain's Waste Clearance Pathway

The glymphatic system, first identified in 2012, functions as the brain's pseudolymphatic network, facilitating the removal of metabolic waste during sleep via perivascular spaces and aquaporin-4 channels on astrocytes. In AD, dysfunction in this system leads to accumulation of toxic proteins, exacerbating neurodegeneration.

Research shows aging impairs glymphatic flow, with reduced clearance linked to AD risk. Lifestyle factors like exercise and sleep optimization help marginally, but structural interventions like LVA could provide a more direct solution by rerouting lymphatic drainage from deep cervical vessels to veins, promoting continuous passive clearance.

Singaporean researchers at Duke-NUS emphasize that while anti-amyloid drugs like lecanemab slow progression, they target production rather than clearance—LVA fills this gap.

Lymphovenous Anastomosis Explained: A Minimally Invasive Technique

LVA, a staple in plastic and reconstructive surgery for lymphedema, involves microsurgically connecting lymphatic vessels (typically 0.2-0.8mm diameter) to nearby veins using supermicrosurgery tools under magnification. For AD, targets are deep cervical lymphatic vessels (dcLVs) draining the brain, located in the neck near the jugular vein.

Step-by-step:

• Preoperative mapping: Indocyanine green (ICG) lymphography identifies functional lymphatics.
• Anesthesia: Local or general, outpatient possible.
• Incision: Small neck incision (2-4cm).
• Anastomosis: Suture 1-2mm vessels (8-0 to 12-0 nylon), bilateral preferred.
• Verification: ICG confirms patency.
• Closure: Sutures removed in 7-10 days.

Dr. Khong-Yik Chew, senior consultant at SGH's Plastic Surgery Department, notes LVA's safety profile from thousands of procedures worldwide.

Preliminary Evidence Supporting LVA in Alzheimer's

Though early, studies—primarily from China—report promising results. Xie et al. (2023) treated over 200 severe AD patients, noting cognitive stabilization. Li et al. (2024) showed PET/MRI glymphatic improvements in six cases. Chen et al. (2025) observed significant MMSE score gains (P=0.022) in 26 patients, with 60% caregiver-reported benefits.

These align with glymphatic impairment theories: MRI metrics like DTI-ALPS correlate with AD severity. LVA's mechanism restores flow without drugs, potentially adjunctive to anti-amyloid therapies.

A pilot trial (NCT06965062) tests cervical LVA in AD, laying groundwork for larger studies.

Singapore's Research Ecosystem: Duke-NUS at the Forefront

Duke-NUS Medical School, Singapore's premier graduate medical institution, excels in neuroscience via its Programme in Neuroscience and Behavioral Disorders and GK Goh Centre. Collaborations with SGH (part of SingHealth) and NNI leverage clinical data from Asia's largest neuroscience network.

Lead author Yu-Hsin Yen (Duke-NUS) and co-authors from NNI Neurosurgery highlight interdisciplinary synergy. SGH's plastic surgery expertise, led by Dr. Chew, bridges microsurgery and neurology.

This reflects Singapore's investment in biomedical research, with Duke-NUS ranking among Asia's top for clinical medicine. For aspiring researchers, tips on academic CVs can help enter this field.

Photo by Chunjiang on Unsplash

Patient Selection and Measuring Success

The review proposes strict criteria: ages 50-80, mild-moderate AD (MMSE 11-26), biomarker confirmation (CSF Aβ/tau, PET). Exclude comorbidities or advanced disease.

Outcomes via:

• Cognitive: MoCA, MMSE, RBANS.
• Imaging: DTI-ALPS MRI, ICG patency.
• Biomarkers: Serial CSF/plasma levels.
• Functional: ADL scales, caregiver reports.

Trials need 1-3 year follow-up to assess durability.

Risks, Limitations, and Ethical Considerations

LVA risks: infection (<1%), bleeding, thrombosis—mitigated by antireflux valves. Oncologic safety established; no brain dissemination fears. Limitations: Small studies, mostly Chinese cohorts; causality unproven; sham controls needed.

Singapore's ethics framework, via SingHealth CIRB, ensures rigorous oversight for future trials.

Future Outlook: Trials and Global Impact

The team calls for multinational RCTs, starting with Singapore-led pilots. Success could extend to Parkinson's, ALS. Singapore's aging crisis (1 in 4 over 65 by 2030) amplifies urgency.

Duke-NUS's role positions it for funding via NMRC, fostering PhD/postdoc opportunities in neuroplastic surgery.Postdoc positions in higher ed.

Singapore's Leadership in Neurodegenerative Research

Beyond LVA, Duke-NUS advances AD via single-cell RNA-seq revealing cell-type contributions. NNRIS integrates 200+ experts. This LVA proposal elevates Singapore globally.

For students, Singapore higher ed opportunities abound in biomed.

Career Pathways in Alzheimer's Research

This study opens doors in neurosurgery, plastic surgery, neuroimaging. Duke-NUS offers MD-PhD tracks; SGH residencies blend clinical-academic paths. Check Rate My Professor for insights on faculty.

Actionable: Pursue neuroscience at NUS/Duke-NUS, specialize in microsurgery.

Photo by Galen Crout on Unsplash

Conclusion: Hope on the Horizon

The Duke-NUS-SGH LVA proposal redefines AD treatment, targeting clearance for lasting impact. As Singapore tackles dementia's rise, such innovations from its universities promise better outcomes. Stay informed via higher education news; explore higher-ed jobs, rate my professor, career advice, university jobs.